NCT06742021 Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
| NCT ID | NCT06742021 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yunnan Cancer Hospital |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 195 participants |
| Start Date | 2024-11-11 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 195 participants in total. It began in 2024-11-11 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. By utilizing two DCE-MRI images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.
Eligibility Criteria
Inclusion Criteria: 1. Tumor size greater than 2 cm 2. Age between 18 and 75 years Exclusion Criteria: 1. Presence of MRI contraindications (e.g., metal implants, pacemaker implantation, etc.) 2. Allergy to gadolinium contrast agents 3. Lesions difficult to delineate on images due to conditions such as atelectasis or diffuse lesions
Contact & Investigator
Lianhua Ye
STUDY DIRECTOR
Ethics Committee of Yunnan Provincial Cancer Hospital
Frequently Asked Questions
Who can join the NCT06742021 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06742021 currently recruiting?
Yes, NCT06742021 is actively recruiting participants. Contact the research team at 3332105746@qq.com for enrollment information.
Where is the NCT06742021 trial being conducted?
This trial is being conducted at Kunming, China.
Who is sponsoring the NCT06742021 clinical trial?
NCT06742021 is sponsored by Yunnan Cancer Hospital. The principal investigator is Lianhua Ye at Ethics Committee of Yunnan Provincial Cancer Hospital. The trial plans to enroll 195 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.